Abstract
Real-time RT-PCR has great advantages for estimating transcript levels in a variety of situations. These include relative rapid assay times (hours), reliability and ease of performing replicate analyses. In contrast, competitive PCR is a very labor-intensive procedure requiring a few days to generate useful data. We compared the same samples from CML patients by both methods. Importantly, we used the Bcr-Abl junction plasmid DNA, which is used as a competitor in the manual competitive PCR assay, to generate a standard curve for the real-time assay. This permitted reporting the real-time data as the number of BCR-ABL transcripts per μg of total RNA, which is the same format used for the competitive PCR assay. In this study, a total of 435 peripheral blood and marrow samples from 285 CML patients were analyzed by RT-PCR; these patients were undergoing therapy by STI-571, interferon, and bone marrow transplantation treatment. Most samples also had assay values for the Philadelphia chromosome (Ph), FISH and Western blotting for the Bcr-Abl oncoprotein. Our findings indicated that the real-time assay was less sensitive than the manual competitive RT-PCR assay (t = 5.118; P < 0.001). Of interest, the transcript levels in cell line mixtures with various ratios of K562/KG-1 (BCR-ABL positive/negative) cells were also significantly higher with the competitive RT-PCR assays than real-time RT-PCR, except for levels of BCR-ABL below 200 transcripts per μg of RNA. In both patient and cell line experiments, dividing the BCR-ABL transcripts by the total ABL transcripts virtually eliminated the difference between real-time BCR-ABL transcript values and quantitative competitive BCR-ABL transcript values, indicating that both BCR-ABL and ABL transcripts were underestimated by the real-time assay. In addition, the increased sensitivity of the nested, competitive RT-PCR was readily apparent in patients with minimal residual disease, which by the real-time were negative in the majority of patients but were positive by nested, competitive RT-PCR in 44.6% (n = 29) of samples analyzed (n = 65). These findings indicate that real-time RT-PCR, when normalized for the total ABL transcripts, can be used to monitor CML patients during therapy, but we suggest that nested, competitive RT-PCR be used to determine BCR-ABL/ABL transcript ratios at low transcript values or especially when real-time analyses are negative.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R . The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine kinase activity Virology 1985 140: 230–238
Davis RL, Konopka JB, Witte ON . Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties Mol Cell Biol 1985 5: 204–213
Rowley JD . A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 1973 243: 290–293
Shtivelman E, Lifshitz B, Gale RP, Canaani E . Fused transcript of abl and bcr genes in chronic myelogenous leukaemia Nature 1985 315: 550–553
Tkachuk DC, Westbrook CA, Andreeff M, Donlon DA, Cleary ML, Surynanarayan K, Home R, Redner A, Gray J, Pinkel D . Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization Science 1990 250: 559–562
Shtalrid M, Talpaz M, Kurzrock R, Kantarjian H, Trujillo J, Gutterman J, Yoffe G, Blick M . Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia Blood 1988 72: 485–490
Guo JQ, Wang JY, Arlinghaus RB . Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients Cancer Res 1991 51: 3048–3051
Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JY, Arlinghaus RB . BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy Blood 1994 15: 3629–3637
Cross NC, Feng L, Bungey J, Goldman JM . Minimal residual disease after bone marrow transplant for chronic myeloid leukemia detected by the polymerase chain reaction Leuk Lymphoma 1993 11: 39–43
Cross NC, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM . Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse Br J Haematol 1993 1: 67–74
Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S, Reiter A, Kuhn C, Berger U, Hehlmann R, Cross NC . Detection and quantification of residual disease in chronic myelogenous leukemia Leukemia 2000 6: 998–1005
Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM . Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation Blood 1993 82: 1929–1936
Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A . Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR Leukemia 1999 11: 1825–1832
Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B . Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation Leukemia 1999 13: 1383–1389
Branford S, Hughes TP, Rudzki Z . Monitoring chronic myeloid leukemia therapy by real-time quantitative PCR in blood is reliable alternative to bone marrow cytogenetics Br J Haematol 1999 107: 587–599
Lozzio CB, Lozzio BB . Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome Blood 1975 45: 321–334
Andersson BS, Collins VP, Kurzrock R, Larkin DW, Childs C, Ost A, Cork A, Trujillo JM, Freireich EJ, Siciliano MJ, Deisseroth AB . KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts Leukemia 1995 9: 2100–2108
Koeffler HP, Lowe L, Golde DW . Amygdalin (Laetrile): effect on clonogenic cells from human myeloid leukemia cell lines and normal human marrow Cancer Treat Rep 1980 1: 105–109
Smith RG, Dev VG, Shannon WA Jr . Characterization for a novel human pre-B leukemia cell line J Immunol 1981 126: 596–602
Cross NC, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders Leukemia 1994 1: 186–189
Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM, Cross NC . Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction Leukemia 1997 11(Suppl. 3): 541–544
Seong D, Kantarjian H, Ro J, Siciliano M . Hypermetaphase FISH for quantitative monitoring of Ph-positive cells in patients With CML during treatment Blood 1995 86: 2343–2349
Faderl S, Talpaz M, Kantarjian HM, Estrov Z . Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making Blood 1999 9: 2755–2759
Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NC, Goldman JM . Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia Blood 2001 97: 1560–1565
Acknowledgements
We would like to thank Dr Goldman for the competitor plasmids, and Dr Feng Lin for advice and suggestions. In addition, we would like to thank Dr Ke Si for help in statistical analysis and we acknowledge expert technical assistance of Qing Wang and Jialing Xu. This research was supported by grants from NIH (CA49639) and the Hendricks Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guo, J., Lin, H., Kantarjian, H. et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 16, 2447–2453 (2002). https://doi.org/10.1038/sj.leu.2402730
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402730
Keywords
This article is cited by
-
Current status and novel strategy of CML
International Journal of Hematology (2021)
-
Development of Hydrogel Microparticle based RT-qPCR for Advanced Detection of BCR-ABL1 Transcripts
BioChip Journal (2019)
-
Colorimetric determination of BCR/ABL fusion genes using a nanocomposite consisting of Au@Pt nanoparticles covered with a PAMAM dendrimer and acting as a peroxidase mimic
Microchimica Acta (2018)
-
Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors
Medical Oncology (2013)
-
Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
Blood Cancer Journal (2012)